Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients

I. Takahashi, Y. Maehara, T. Kusumoto, S. Kohnoe, Y. Kakeji, H. Baba, K. Sugimachi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We have found that elevation of preoperative serum sialyl-Tn antigen (STN) levels is associated with a poor prognosis for gastric cancer patients, and these high levels remain in the advanced stage of the disease. We have now examined findings with the combined assay of STN and carcinoembryonic antigen (CEA) levels with regard to prediction of the prognosis of gastric cancer patients. Serum CEA levels and STN levels were determined preoperatively in 349 Japanese patients with gastric cancer. The patients were divided into four groups: (A) the CEA (-) STN (-) group (CEA ≤ or = 5 ng ml-1, STN ≤ or = 45 U ml-1, n = 286); (B) the CEA (-) STN (+) group (CEA < or = 5 ng ml-1, STN > 45 U ml-1, n = 31); (C) the CEA (+) STN (-) group (CEA > 5 ng ml-1, STN < or = 45 U ml-1, n = 17); and (D) the CEA (+) STN (+) group (CEA ≤ 5 ng ml-1, STN > 45 U ml-1, n = 15). Clinicopathological features and the prognosis of these groups were examined. The distribution of two markers showed no significant correlation. The patients in the CEA (+) STN (+) group (group D) had more advanced disease than the patients in CEA (-) STN (-) group (group A); tumour size was larger, serosal invasion was prominent, lymphatic and vascular involvement was frequent and the tumour was more infiltrative. Lymph node metastasis and hepatic metastasis were more common. Total gastrectomy was usually performed, and the non-curative rate was higher. The 5-year survival of patients in the CEA (+) STN (+) (group D) was 14.5 ± 9.5%, that is lower than that of patients in any other group [CEA (+) STN (-) (group C) 44.1 ± 12.7% (P < 0.05); CEA (-) STN (+) (group B) 60.1 ± 9.5% (P > 0.05); CEA (-) STN (-) (group A) 77.6 ± 9.5% (P < 0.05)]. This combined assay of these markers will aid in estimating the prognosis and selecting appropriate drugs and care for gastric cancer patients.

Original languageEnglish
Pages (from-to)163-166
Number of pages4
JournalBritish journal of cancer
Volume69
Issue number1
DOIs
Publication statusPublished - Jan 1994

Fingerprint

Carcinoembryonic Antigen
Stomach Neoplasms
Serum
sialosyl-Tn antigen
Neoplasm Metastasis
Gastrectomy
Blood Vessels
Neoplasms
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients. / Takahashi, I.; Maehara, Y.; Kusumoto, T.; Kohnoe, S.; Kakeji, Y.; Baba, H.; Sugimachi, K.

In: British journal of cancer, Vol. 69, No. 1, 01.1994, p. 163-166.

Research output: Contribution to journalArticle

Takahashi, I. ; Maehara, Y. ; Kusumoto, T. ; Kohnoe, S. ; Kakeji, Y. ; Baba, H. ; Sugimachi, K. / Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients. In: British journal of cancer. 1994 ; Vol. 69, No. 1. pp. 163-166.
@article{2b9b84f23aaf49398a67268949ccec84,
title = "Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients",
abstract = "We have found that elevation of preoperative serum sialyl-Tn antigen (STN) levels is associated with a poor prognosis for gastric cancer patients, and these high levels remain in the advanced stage of the disease. We have now examined findings with the combined assay of STN and carcinoembryonic antigen (CEA) levels with regard to prediction of the prognosis of gastric cancer patients. Serum CEA levels and STN levels were determined preoperatively in 349 Japanese patients with gastric cancer. The patients were divided into four groups: (A) the CEA (-) STN (-) group (CEA ≤ or = 5 ng ml-1, STN ≤ or = 45 U ml-1, n = 286); (B) the CEA (-) STN (+) group (CEA < or = 5 ng ml-1, STN > 45 U ml-1, n = 31); (C) the CEA (+) STN (-) group (CEA > 5 ng ml-1, STN < or = 45 U ml-1, n = 17); and (D) the CEA (+) STN (+) group (CEA ≤ 5 ng ml-1, STN > 45 U ml-1, n = 15). Clinicopathological features and the prognosis of these groups were examined. The distribution of two markers showed no significant correlation. The patients in the CEA (+) STN (+) group (group D) had more advanced disease than the patients in CEA (-) STN (-) group (group A); tumour size was larger, serosal invasion was prominent, lymphatic and vascular involvement was frequent and the tumour was more infiltrative. Lymph node metastasis and hepatic metastasis were more common. Total gastrectomy was usually performed, and the non-curative rate was higher. The 5-year survival of patients in the CEA (+) STN (+) (group D) was 14.5 ± 9.5{\%}, that is lower than that of patients in any other group [CEA (+) STN (-) (group C) 44.1 ± 12.7{\%} (P < 0.05); CEA (-) STN (+) (group B) 60.1 ± 9.5{\%} (P > 0.05); CEA (-) STN (-) (group A) 77.6 ± 9.5{\%} (P < 0.05)]. This combined assay of these markers will aid in estimating the prognosis and selecting appropriate drugs and care for gastric cancer patients.",
author = "I. Takahashi and Y. Maehara and T. Kusumoto and S. Kohnoe and Y. Kakeji and H. Baba and K. Sugimachi",
year = "1994",
month = "1",
doi = "10.1038/bjc.1994.27",
language = "English",
volume = "69",
pages = "163--166",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients

AU - Takahashi, I.

AU - Maehara, Y.

AU - Kusumoto, T.

AU - Kohnoe, S.

AU - Kakeji, Y.

AU - Baba, H.

AU - Sugimachi, K.

PY - 1994/1

Y1 - 1994/1

N2 - We have found that elevation of preoperative serum sialyl-Tn antigen (STN) levels is associated with a poor prognosis for gastric cancer patients, and these high levels remain in the advanced stage of the disease. We have now examined findings with the combined assay of STN and carcinoembryonic antigen (CEA) levels with regard to prediction of the prognosis of gastric cancer patients. Serum CEA levels and STN levels were determined preoperatively in 349 Japanese patients with gastric cancer. The patients were divided into four groups: (A) the CEA (-) STN (-) group (CEA ≤ or = 5 ng ml-1, STN ≤ or = 45 U ml-1, n = 286); (B) the CEA (-) STN (+) group (CEA < or = 5 ng ml-1, STN > 45 U ml-1, n = 31); (C) the CEA (+) STN (-) group (CEA > 5 ng ml-1, STN < or = 45 U ml-1, n = 17); and (D) the CEA (+) STN (+) group (CEA ≤ 5 ng ml-1, STN > 45 U ml-1, n = 15). Clinicopathological features and the prognosis of these groups were examined. The distribution of two markers showed no significant correlation. The patients in the CEA (+) STN (+) group (group D) had more advanced disease than the patients in CEA (-) STN (-) group (group A); tumour size was larger, serosal invasion was prominent, lymphatic and vascular involvement was frequent and the tumour was more infiltrative. Lymph node metastasis and hepatic metastasis were more common. Total gastrectomy was usually performed, and the non-curative rate was higher. The 5-year survival of patients in the CEA (+) STN (+) (group D) was 14.5 ± 9.5%, that is lower than that of patients in any other group [CEA (+) STN (-) (group C) 44.1 ± 12.7% (P < 0.05); CEA (-) STN (+) (group B) 60.1 ± 9.5% (P > 0.05); CEA (-) STN (-) (group A) 77.6 ± 9.5% (P < 0.05)]. This combined assay of these markers will aid in estimating the prognosis and selecting appropriate drugs and care for gastric cancer patients.

AB - We have found that elevation of preoperative serum sialyl-Tn antigen (STN) levels is associated with a poor prognosis for gastric cancer patients, and these high levels remain in the advanced stage of the disease. We have now examined findings with the combined assay of STN and carcinoembryonic antigen (CEA) levels with regard to prediction of the prognosis of gastric cancer patients. Serum CEA levels and STN levels were determined preoperatively in 349 Japanese patients with gastric cancer. The patients were divided into four groups: (A) the CEA (-) STN (-) group (CEA ≤ or = 5 ng ml-1, STN ≤ or = 45 U ml-1, n = 286); (B) the CEA (-) STN (+) group (CEA < or = 5 ng ml-1, STN > 45 U ml-1, n = 31); (C) the CEA (+) STN (-) group (CEA > 5 ng ml-1, STN < or = 45 U ml-1, n = 17); and (D) the CEA (+) STN (+) group (CEA ≤ 5 ng ml-1, STN > 45 U ml-1, n = 15). Clinicopathological features and the prognosis of these groups were examined. The distribution of two markers showed no significant correlation. The patients in the CEA (+) STN (+) group (group D) had more advanced disease than the patients in CEA (-) STN (-) group (group A); tumour size was larger, serosal invasion was prominent, lymphatic and vascular involvement was frequent and the tumour was more infiltrative. Lymph node metastasis and hepatic metastasis were more common. Total gastrectomy was usually performed, and the non-curative rate was higher. The 5-year survival of patients in the CEA (+) STN (+) (group D) was 14.5 ± 9.5%, that is lower than that of patients in any other group [CEA (+) STN (-) (group C) 44.1 ± 12.7% (P < 0.05); CEA (-) STN (+) (group B) 60.1 ± 9.5% (P > 0.05); CEA (-) STN (-) (group A) 77.6 ± 9.5% (P < 0.05)]. This combined assay of these markers will aid in estimating the prognosis and selecting appropriate drugs and care for gastric cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0028088976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028088976&partnerID=8YFLogxK

U2 - 10.1038/bjc.1994.27

DO - 10.1038/bjc.1994.27

M3 - Article

C2 - 8286201

AN - SCOPUS:0028088976

VL - 69

SP - 163

EP - 166

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -